Novavax Inc. just got a critical regulatory assist for its experimental seasonal flu vaccine, news that boosted its stock price and gave a glimmer of hope for its first potential product to hit the market sooner, should it win final approval. The Gaithersburg biotech announced Wednesday that the Food and Drug Administration has granted fast-track status to NanoFlu, Novavax’s flu vaccine for adults ages 65 and older, a move that expedites the drug’s review process. This decision follows the FDA’s…
from https://www.bizjournals.com/baltimore/news/2020/01/16/novavax-earns-key-fda-status-for-its-flu-vaccine.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/190289398097
No comments:
Post a Comment